Your browser is no longer supported. Please, upgrade your browser.
GMED Globus Medical, Inc. monthly Stock Chart
GMED [NYSE]
Globus Medical, Inc.
Index- P/E39.33 EPS (ttm)1.45 Insider Own1.56% Shs Outstand99.64M Perf Week18.12%
Market Cap5.74B Forward P/E31.86 EPS next Y1.79 Insider Trans-6.42% Shs Float73.14M Perf Month24.88%
Income147.90M PEG3.73 EPS next Q-0.11 Inst Own94.71% Short Float6.17% Perf Quarter14.95%
Sales793.00M P/S7.24 EPS this Y-1.50% Inst Trans0.38% Short Ratio3.52 Perf Half Y6.69%
Book/sh13.68 P/B4.16 EPS next Y103.42% ROA10.10% Target Price56.00 Perf Year14.07%
Cash/sh2.74 P/C20.74 EPS next 5Y10.56% ROE11.00% 52W Range33.41 - 60.15 Perf YTD-3.35%
Dividend- P/FCF52.10 EPS past 5Y9.40% ROI9.80% 52W High-5.39% Beta0.98
Dividend %- Quick Ratio4.40 Sales past 5Y10.60% Gross Margin76.40% 52W Low70.34% ATR2.13
Employees2000 Current Ratio6.60 Sales Q/Q4.20% Oper. Margin20.60% RSI (14)67.39 Volatility4.68% 3.30%
OptionableYes Debt/Eq0.00 EPS Q/Q-22.50% Profit Margin18.70% Rel Volume0.78 Prev Close57.82
ShortableYes LT Debt/Eq0.00 EarningsAug 05 AMC Payout0.00% Avg Volume1.28M Price56.91
Recom2.30 SMA2016.66% SMA5015.55% SMA20012.93% Volume994,974 Change-1.57%
Aug-06-20Upgrade Northland Capital Market Perform → Outperform $65
Aug-06-20Reiterated Needham Buy $60 → $65
Jul-21-20Initiated Northland Capital Market Perform $50
Jul-06-20Downgrade Piper Sandler Overweight → Neutral $60 → $50
May-08-20Reiterated Needham Buy $63 → $60
Mar-18-20Upgrade BTIG Research Neutral → Buy $46
Jan-08-20Initiated SunTrust Buy $67
Dec-12-19Upgrade Wells Fargo Market Perform → Outperform $63
Aug-02-19Reiterated Needham Buy $52 → $56
May-24-19Downgrade Wells Fargo Outperform → Market Perform $41
May-03-19Reiterated Needham Buy $57 → $52
Feb-28-19Upgrade UBS Neutral → Buy $55
Jan-02-19Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-02-18Reiterated Needham Buy $58 → $65
Jun-27-18Downgrade BofA/Merrill Neutral → Underperform
Jun-01-18Initiated Cantor Fitzgerald Overweight
May-03-18Reiterated Needham Buy $57 → $58
Apr-04-18Upgrade Needham Hold → Buy $57
Mar-28-18Reiterated Leerink Partners Outperform $56 → $60
Jan-02-18Upgrade Morgan Stanley Equal-Weight → Overweight
Aug-05-20 06:35PM  
04:15PM  
Aug-04-20 11:25AM  
Jul-29-20 12:33PM  
Jul-21-20 04:15PM  
Jun-23-20 07:40PM  
Jun-09-20 10:05AM  
May-27-20 08:09AM  
May-20-20 03:56PM  
May-09-20 09:34AM  
May-08-20 09:30PM  
10:23AM  
07:00AM  
May-07-20 08:50PM  
04:15PM  
Apr-30-20 07:36AM  
Apr-16-20 04:30PM  
Apr-07-20 10:23AM  
Mar-26-20 09:37AM  
Mar-21-20 11:30AM  
Mar-18-20 03:28PM  
09:53AM  
Mar-12-20 08:00AM  
Mar-11-20 05:40PM  
Mar-04-20 01:35AM  
Feb-21-20 08:34AM  
Feb-20-20 06:05PM  
04:15PM  
Feb-13-20 12:31PM  
Feb-06-20 04:30PM  
Feb-04-20 04:30PM  
Jan-31-20 09:41AM  
Jan-28-20 06:13PM  
Jan-16-20 09:43AM  
Jan-09-20 10:19AM  
08:39AM  
Jan-08-20 04:30PM  
04:06PM  
Jan-02-20 09:43AM  
Dec-19-19 09:19AM  
Dec-16-19 11:26AM  
Dec-13-19 04:15PM  
08:10AM  
Dec-10-19 07:36AM  
Dec-08-19 03:47PM  
Dec-06-19 11:31AM  
Dec-03-19 01:12PM  
Nov-13-19 01:25AM  
Nov-12-19 09:41AM  
Nov-11-19 01:12PM  
Nov-07-19 10:23AM  
Nov-06-19 06:25PM  
04:15PM  
Oct-31-19 11:15AM  
Oct-30-19 10:34AM  
Oct-28-19 08:58AM  
Oct-24-19 10:55AM  
Oct-16-19 04:15PM  
Oct-02-19 09:09AM  
Sep-24-19 08:30AM  
Sep-19-19 04:15PM  
Sep-18-19 11:16AM  
Sep-13-19 07:48PM  
Sep-06-19 07:36AM  
Sep-05-19 09:40AM  
Aug-31-19 09:31AM  
Aug-15-19 09:30AM  
Aug-14-19 09:30AM  
Aug-07-19 03:34AM  
Aug-02-19 11:38AM  
11:23AM  
Aug-01-19 07:15PM  
04:15PM  
Jul-25-19 10:33AM  
Jul-22-19 09:13AM  
Jul-15-19 08:00AM  
Jul-03-19 06:12AM  
Jun-27-19 04:30PM  
Jun-20-19 01:35PM  
Jun-08-19 09:03AM  
Jun-01-19 09:32AM  
May-30-19 04:15PM  
May-24-19 08:23AM  
May-23-19 04:15PM  
May-09-19 12:54PM  
May-06-19 04:27AM  
May-03-19 06:37AM  
May-02-19 08:58PM  
07:35PM  
06:32PM  
04:15PM  
May-01-19 10:04AM  
Apr-25-19 03:51PM  
10:34AM  
Apr-17-19 05:01PM  
Apr-16-19 09:48AM  
Apr-15-19 04:30PM  
Apr-07-19 08:41PM  
Apr-01-19 10:27AM  
07:29AM  
Globus Medical, Inc., a medical device company, focuses on the development and commercialization of implants that heal patients with musculoskeletal disorders. Its spine product portfolio includes a range of implant and surgical approach options that can be used to treat degenerative, deformity, tumor, and trauma conditions affecting the spine from the occiput to the sacrum. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and regenerative biologic products, such as allografts and synthetic alternatives that are adjunctive treatments used in combination with stabilizing implant hardware. In addition, it provides motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous distraction devices, and interventional pain management solutions to treat vertebral compression fractures; imaging, navigation, and robotic assisted surgery technology solutions; and hip and knee joint solutions, as well as distributes human cell, tissue, and cellular and tissue based products. Further, the company offers expandable spacer products, which include RISE, RISE-L, CALIBER, CALIBER-L, ALTERA, ELSA, ELSA-ATP, SABLE, MAGNIFY, MAGNIFY-S, FORTIFY, and XPand; CREO thoracolumbar stabilization platform that offers instruments and implants for treating pathologies; CREO MIS and CREO MCS, options designed for less invasive surgery and minimal muscle disruption; CREO Derotation and CREO Rod Link Reducer systems, which help to streamline various derotation maneuvers for deformity correction; CREO Addition that provides a range of connectors; and CREO Fenestrated, a cement augmented pedicle screw system for patients with advanced stage tumors and limited life expectancy, as well as QUARTEX, an occipito-cervico-thoracic stabilization system. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Douglas Robert AndrewDirectorJul 22Buy47.7569032,9481,390Jul 24 05:00 PM
Douglas Robert AndrewDirectorJun 22Buy48.2070033,740700Jun 24 04:20 PM
Huller KellySVP, GC, Corporate SecretaryJun 11Option Exercise11.289,076102,3779,076Jun 15 04:33 PM
Huller KellySVP, GC, Corporate SecretaryJun 11Sale51.009,076462,8760Jun 15 04:33 PM
Scavilla Daniel TEVP, Chief Commercial OfficerMay 21Option Exercise25.48100,0002,548,250100,000May 26 04:30 PM
Scavilla Daniel TEVP, Chief Commercial OfficerMay 21Sale55.09100,0005,509,0000May 26 04:30 PM
Huller KellySVP, General CounselDec 17Option Exercise11.863,07636,4813,076Dec 19 04:38 PM
Huller KellySVP, General CounselDec 17Sale58.906,460380,4940Dec 19 04:38 PM
Davidar David DDirectorNov 07Sale54.0410,000540,400215,967Nov 12 04:40 PM
Davidar David DDirectorNov 07Sale54.0038,0002,052,000666,775Nov 12 04:40 PM
Huller KellySVP, General CounselNov 07Sale55.903,000167,7003,384Nov 12 04:37 PM
Huller KellySVP, General CounselNov 01Sale52.903,000158,7006,384Nov 04 04:31 PM
Davidar David DDirectorAug 16Option Exercise24.1050,0001,205,000754,775Aug 19 04:46 PM
Davidar David DDirectorAug 16Sale49.3350,0002,466,505704,775Aug 19 04:46 PM